Changing Global Epidemiology of Inflammatory Bowel Diseases-Sustaining Healthcare Delivery into the 21st Century.

Crohn’s disease (CD) and ulcerative colitis (UC) have emerged as global diseases. They affect over 2 million individuals in the North America, 3.2 million in Europe, and millions more worldwide. […]

» Read more

Integrated Psychological Care Reduces Healthcare Costs at a Hospital-Based Inflammatory Bowel Disease Service.

Inflammatory bowel diseases (IBD) are associated with high psychosocial burden and economic cost. Integrating psychological care into routine management might lead to savings. We performed a 2-year investigation of the […]

» Read more

Assessing National Trends and Disparities in Ambulatory, Emergency Department, and Inpatient Visits for Inflammatory Bowel Disease in the United States (2005-2016).

Patients with inflammatory bowel diseases (IBD) require repeated healthcare encounters, although the focus of care differs when patients are seen in ambulatory, emergency department (ED), or inpatient settings. We examined […]

» Read more

First- and Second-line Pharmacotherapies for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis.

We compared the efficacy and safety of different first-line (biologic-na├»ve) and second-line (prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moderate to severely active ulcerative colitis […]

» Read more

A Scoring System to Determine Patients’ Risk of Colectomy Within 1 y After Hospital Admission for Acute Severe Ulcerative Colitis.

There is consensus on the criteria used to define acute severe ulcerative colitis (ASUC) and on patient management, but it has been a challenge to identify patients at risk for […]

» Read more

Inpatient Management of Inflammatory Bowel Disease Related Complications.

Despite advances in therapeutic options, a sizeable proportion of patients with inflammatory bowel disease require hospitalization or surgery during their lifetime. While current treatment guidelines for the management of ulcerative […]

» Read more

Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis.

New oral therapeutic agents are needed for patients with ulcerative colitis (UC) who are unresponsive or intolerant to conventional therapy.We performed a double-blind, phase 2 trial of adults with active […]

» Read more

How do we Treat Inflammatory Bowel Diseases to Aim For Endoscopic Remission?

Crohn’s disease and ulcerative colitis are heterogeneous conditions which may manifest with one or more of a constellation of abnormal symptoms, elevated biomarkers, and/or objective evidence of inflammation on endoscopic […]

» Read more

A Users Guide to De-escalating Immunomodulator and Biologic Therapy in Inflammatory Bowel Disease.

De-escalation of immunomodulators and biologic agents in inflammatory bowel disease is frequently discussed with patients and must weigh the risk of continued medical therapy with the risk of disease recurrence. […]

» Read more

Exposure to Intravenous Opioids is Associated With Future Exposure to Opioids in Hospitalized Patients With Inflammatory Bowel Diseases.

Opioid use is associated with increased mortality in patients with inflammatory bowel diseases (IBD). Hospitalized patients with IBD often receive high-potency intravenous opioids (IVOPIs). It is not known whether exposure […]

» Read more

Complete Resolution of Mucosal Neutrophils Associates With Improved Long-Term Clinical Outcomes of Patients With Ulcerative Colitis.

We investigated correlations between histologic features of the colonic mucosa in patients with ulcerative colitis (UC) and clinical outcomes over a 3-year follow-up period.We obtained baseline biopsies from all colorectal […]

» Read more

Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis: Ustekinumab PK and exposure-response in UC.

The efficacy of antibody-based therapeutics depends on their pharmacokinetics. The pharmacokinetic and exposure response profiles of ustekinumab, a monoclonal antibody against interleukin 12/interleukin 23, are known in patients with Crohn’s […]

» Read more

Use of Cross-sectional Imaging for Tight Monitoring of Inflammatory Bowel Diseases.

A “treat-to-target” strategy with close monitoring of intestinal inflammation is recommended in inflammatory bowel disease (IBD). Ileocolonoscopy (CS) remains the gold-standard for assessing disease activity in IBD but is a […]

» Read more

Histologic Healing is More Strongly Associated with Clinical Outcomes in Ileal Crohn’s Disease than Endoscopic Healing.

Deep remission, based on clinical remission and evidence of healing during endoscopic evaluation, are goals of medical treatments for Crohn’s disease (CD). We investigated whether histologic healing is associated with […]

» Read more

Identifying Patients With Inflammatory Bowel Diseases at High vs Low Risk of Complications.

People with Crohn’s disease and ulcerative colitis have varying presentations and clinical consequences of their disease. Patients commonly ask about their prognosis, and what this diagnosis means for them. They […]

» Read more

Complete Endoscopic Healing Associated With Better Outcomes Than Partial Endoscopic Healing in Patients With Crohn’s Disease.

Mucosal healing (MH) has been associated with a good outcomes of patients with Crohn’s disease (CD). It is not clear what levels of endoscopic healing, based on CD endoscopic index […]

» Read more
1 2 3 4